Open AccessAZELAIC ACID ATTENUATESROTENONE-INDUCED BEHAVIOURAL ALTERATIONS IN PARKINSON’S DISEASE RAT MODEL
Author(s) -
Neha Sharma,
Navneet Khuranaa,
Arunachalam Muthuraman,
Puneet Utreja
Publication year - 2020
Publication title -
plant archives/plant archives
Language(s) - English
Resource type - Journals
eISSN - 2581-6063
pISSN - 0972-5210
DOI - 10.51470/plantarchives.2021.v21.s1.383
Subject(s) - rotenone , parkinson's disease , azelaic acid , pharmacology , catalepsy , levodopa , carbidopa , chemistry , medicine , biochemistry , disease , dopamine , mitochondrion , haloperidol
In the current study, we investigated the anti-Parkinson’s effect of azelaic acid (AA; 20 mg/kg, 40mg/kg, 80 mg/kg p.o.) against rotenone (2 mg/kg s.c.) induced Parkinson’s disease (PD) rat model. Rotenone was administered continuously for 35 days and caused behavioural alterations such as catalepsy, rigidity in muscles, posture instability and decrease in body weight, locomotor activity, and rearing behaviour.AAshowed significant (p<0.05) reversal in behavioural alterations induced by rotenone at 80 mg/kg dose on 28th and 35th day of treatment. Administration of azelaic acid along with levodopa-carbidopa (100mg/kg+25mg/kg p.o.) also showed significant reversal of behavioural alterations induced by rotenone and this effect was comparable to the effect of levodopa-carbidopa treatment group. The study proved the ameliorative effect of azelaic acidin rotenone induced PD rat model indicating its possible therapeutic potential for this devastating disease.